Intervention Protocol

Hypomethylating agents for patients with myelodysplastic syndrome

  1. Kathrin Bauer1,*,
  2. Franz Hutzschenreuter1,
  3. Nicole Skoetz1,
  4. Karl-Anton Kreuzer2,
  5. Ina Monsef1,
  6. Andreas Engert1

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 5 OCT 2011

DOI: 10.1002/14651858.CD009340


How to Cite

Bauer K, Hutzschenreuter F, Skoetz N, Kreuzer KA, Monsef I, Engert A. Hypomethylating agents for patients with myelodysplastic syndrome (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 10. Art. No.: CD009340. DOI: 10.1002/14651858.CD009340.

Author Information

  1. 1

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

  2. 2

    University Hospital of Cologne, Department I of Internal Medicine, Cologne, Germany

*Kathrin Bauer, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. kathrin.bauer@uk-koeln.de.

Publication History

  1. Publication Status: New
  2. Published Online: 5 OCT 2011

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The main objective of this systematic review is to evaluate the role of hypomethylating agents (that is 5-Aza, DAC) for patients with MDS. For this purpose we will critically, systematically and statistically analyse the efficacy of hypomethylating agents compared to best supportive care or no treatment as well as to other agents or chemotherapy regimens with regard to overall survival (OS), treatment-related mortality (TRM), complete response rate (CR), progression-free survival (PFS) or similar outcomes, quality of life, adverse events and the time to transformation to AML.